AVM Biotechnology

About:

AVM Biotechnology is a clinical stage company.

Website: http://avmbiotech.com

Twitter/X: avmbiotech

Top Investors: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases

Description:

AVM is a clinical-stage biotech company located in Seattle WA led by Dr. Theresa Deisher, a biotech veteran with a productive history including 47 patents and 4 discoveries in clinical trials. The company's lead drug AVM0703, an innovative formulation of dexamethasone, when given at suprapharmacologic doses has a novel mechanism of action to mobilize the body's own natural supercharged immune cells. AVM0703 could be the first choice for no-option cancer, autoimmunity, and infectious disease. AVM Biotechnology has a Scientific Advisory Board including well-respected leaders in cancer and immunology.